Early apixaban therapy after ischemic stroke in patients with atrial fibrillation

ConclusionsSymptomatic HT rates are likely to be low in randomized trials of DOAC initiation post-stroke. Recurrent ischemic stroke may be the major clinical outcome. These data may be used as expected event rates when calculating sample size requirements for future safety/efficacy trials of early versus late DOAC initiation after AF-related stroke.
Source: Journal of Neurology - Category: Neurology Source Type: research